Podcasts about ironwood pharmaceuticals

Synopsis: Abe Ceesay, CEO of Rapport Therapeutics, sits down with host Rahul Chaturvedi to reveal how precision neuroscience is driving revolutionary treatments for neurological disorders. They explore Rapport's cutting-edge lead program targeting focal epilepsy and discuss the groundbreaking advancements that are reshaping the landscape of drug development. Abe also shares his dynamic leadership journey, offering insights into the biotech industry's future and how innovative approaches are delivering life-changing treatments. Don't miss this powerful discussion on the future of precision medicine and the hope it brings to patients with neurological conditions. Biography: Abe brings nearly two decades of biopharmaceutical industry experience to Rapport. He served as President of Cerevel Therapeutics from May 2021 through February 2023, and was previously CEO of Tiburio Therapeutics, where he built a fully integrated company that led to the investigational new drug enablement for a rare neuroendocrine tumor. Prior to joining Tiburio, Mr. Ceesay held positions including Chief Operating Officer at scPharmaceuticals, Head of Commercial at Keryx Biopharmaceuticals, Vice President of Marketing at Ironwood Pharmaceuticals, and roles of increasing responsibility at Sanofi, formerly Genzyme. Mr. Ceesay serves as Chairman of the Board for Life Science Cares and on the Board of Trustees at The Museum of Science in Boston. He earned his bachelor's degree from Ithaca College and Master of Business Administration from Suffolk University's Sawyer School of Management.

Lori Plung is an IBD Patient Advocate who was diagnosed with Crohn's Disease at a young age, and later Short Bowel Syndrome (SBS), a condition where a person's small intestine is damaged or partially missing. Lori joins us to share her patient journey, how her quality of life has improved since her diagnosis, and offers advice for those living with SBS and their loved ones. Lori also shares a message of hope for anyone who's diagnosed with a life altering condition. This episode is brought to you by Ironwood Pharmaceuticals.   

Short Bowel Syndrome (SBS), a condition where a person's small intestine is damaged or partially missing, can cause serious symptoms including a failure to absorb enough nutrients from food for their body to thrive. Dr. Christopher Schmoyer, a Gastroenterologist from the University of Pennsylvania, joins us to explain the causes of SBS, how it is diagnosed and what treatment options are available. We also discuss long-term management of SBS and the lifestyle modifications that can help improve an SBS patient's quality of life. This episode is brought to you by Ironwood Pharmaceuticals.

In this podcast episode, Tom McCourt, chief executive officer of Ironwood Pharmaceuticals, discusses the evolving relationship between physicians and pharma, breakthroughs in GI drugs and more. •    Intro :59 •    Welcome to this episode of Gut Talk 1:23 •    The interview/about McCourt 1:32 •    Tell us about your family and where you grew up. 2:15 •    What did you take away from your football career at University of Wisconsin? 4:19 •    How long were you a clinical pharmacist?  7:57 •    McCourt on his experience as a health science associate.  8:55 •    Where is the line between academics and the pharma industry? 10:49 •    When you launched drugs like omeprazole and esomeprazole, did you have any idea what impact they would have? 13:00 •    What changed to make the pharma industry go from respected to villainized? 16:39 •    What's your perspective on innovation and billing architecture for pharmaceuticals? […] Where do you think we're going to see the most exciting changes in the near-term? 19:33 •    Chey and McCourt on challenges the US health care system faces in comparison to other countries. 24:47 •    How can we make breakthrough drugs and technology available to everyone without stifling innovation? 27:05 •    Did patients valuing their quality-of-life factor into your decision to switch from AmGen to Ironwood Pharmaceuticals? 29:12 •    From a pharmaceutical perspective, do you think there are examples of successful health policy? 36:30 •    Thank you, Tom 42:13 •    Thanks for listening 43:20 Tom McCourt is the chief executive officer of Ironwood Pharmaceuticals, a commercial biotechnology company working to revolutionize the treatment of gastrointestinal (GI) diseases and redefine the standard of care for millions of patients.  We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from McCourt, follow @ironwoodpharma on X. Disclosures: Berry and Chey report no relevant financial disclosures. McCourt is chief executive officer and a member of the board of directors of Ironwood Pharmaceuticals; serves on the board of directors and member of the compensation committee of Pliant Therapeutics, Inc., a public company, and on the board of trustees for the American Society of Gastrointestinal Endoscopy (ASGE).    

Meet Our Guest: Angelika Fretzen, Ph.D., M.B.A. is the Wyss Institute's Technology Translation Director and COO. She earned her Ph.D. in organic chemistry at the University of Geneva, Switzerland, and gained postdoctoral experience in the laboratory of Professor Gregory Verdine at Harvard University. Following her academic training, Dr. Fretzen pursued her M.B.A. at Suffolk University, Boston, and subsequently held leadership positions at Ironwood Pharmaceuticals, and at Catabasis Pharmaceuticals in Cambridge, MA, where she was Senior Vice President of Product Development.Key Insights: Dr. Fretzen discusses her experience of being a woman in STEM and how she encourages younger generations to join the STEM community.● From Germany to Harvard. Dr. Fretzen was young when she took interest in STEM. She quickly realized this was seen as an unorthodox path growing up in Germany, but nevertheless prevailed and made it to her current position at the Wyss Institute at Harvard University.● A Career In Chemistry. Going from industry to academia, she enjoyed this career turn. Her industry experience enabled her to gain a deep understanding of the processes involved in developing and de-risking therapeutic products from pre-clinical stages to the clinical market.● The Only Woman in The Room. Dr. Fretzen's impressive and innovative career has sometimes caused her to be the only woman in the room. Even if this was sometimes a difficult path to forge, she believes that no matter what you do, be sure to follow your passion.This episode is hosted by Sandra Fenwick, Former CEO, Boston Children's Hospital.Relevant Links: Read more about Angelika FretzenWyss Institute at Harvard University

Today we're going to talk about the power of using analytics to improve your company and team performance. To help me discuss this topic, I'd like to welcome Steve Leeds, Vice President of business analytics for Ironwood Pharmaceuticals and author of The Analytic Detective. RESOURCES The Agile Brand podcast website: https://www.gregkihlstrom.com/theagilebrandpodcast   Sign up for The Agile Brand newsletter here: https://www.gregkihlstrom.com    Get the latest news and updates on LinkedIn here: https://www.linkedin.com/company/the-agile-brand/    For consulting on marketing technology, customer experience, and more visit GK5A: https://www.gk5a.com  The Agile Brand podcast is brought to you by TEKsystems. Learn more here: https://www.teksystems.com/versionnextnow

Today we're going to talk about the power of using analytics to improve your company and team performance. To help me discuss this topic, I'd like to welcome Steve Leeds, Vice President of business analytics for Ironwood Pharmaceuticals and author of The Analytic Detective. RESOURCES The Agile Brand podcast website: https://www.gregkihlstrom.com/theagilebrandpodcast   Sign up for The Agile Brand newsletter here: https://www.gregkihlstrom.com    Get the latest news and updates on LinkedIn here: https://www.linkedin.com/company/the-agile-brand/    For consulting on marketing technology, customer experience, and more visit GK5A: https://www.gk5a.com  The Agile Brand podcast is brought to you by TEKsystems. Learn more here: https://www.teksystems.com/versionnextnow

Opening Doors episodes of the MAPS Elevate Podcast Series give Medical Affairs professionals the opportunity to tell the story of how they found their way into the profession and to offer advice to others seeking Medical Affairs positions. Here MAPS co-founder, Kirk Shepard, speaks with Niha Yerneni, Medical Scientific Affairs Manager at Ironwood Pharmaceuticals about joining Medical Affairs and, among other ideas, whether a person with recent postgraduate degree (MD, PhD, PharmD) can be successful in immediately seeking a position in industry or if fellowship or other industry training opportunities are necessary gatekeepers for entry.

Irritable bowel syndrome (IBS) affects up to 4% of the U.S. population and impacts patients across the various quality of life domains. In this episode of the NP Pulse: The Voice of the Nurse Practitioner® podcast, nurse practitioners Kimberly Kearns and Nastassja Williams discuss the diagnosis and management of IBS as well as the impact IBS has on patients. This podcast is supported by an independent grant from Ironwood Pharmaceuticals and Allergan, an AbbVie company. Supplements to this episode include a resource tool for NPs, Navigating IBS Diagnosis and Treatment, and a patient handout, Improving Quality of Life With IBS. Visit the AANP website to learn more about the benefits of membership; access a variety of useful resources organized by therapeutic area; save on registration for the 2022 AANP Fall Conference in Anaheim, California, Sept. 15-18 and much more. 

Growing up in a family of medical professionals inspired Georgia to focus her education—and ultimately her career—on health care. Though she always knew from a young age that she wanted to differentiate herself in some way. During pharmacy school, she joined her IPhO chapter and it exposed her to a whole new side of pharmacy that she hadn't known much about. And that's where her path to industry began. Today, Georgia is in a dynamic patient safety and regulatory role with Ironwood Pharmaceuticals. She discusses how she prepared for and secured her fellowship, her experience at Ironwood so far, and important advice for students about how to make sure their prospective fellowship company is the right fit for them—not just the other way around!

Tom McCourt, CEO of Ironwood Pharmaceuticals, talks about his 30-plus years in the gastrointestinal space, including his experiences bringing top GI medicines Prilosec, Nexium, Entocort, Zelnorm, and Linzess to market.

Angelika Fretzen is the Wyss Institute's Chief Operating Officer & Technology Translation Director, applying her technology and entrepreneurial business development experience to steer the Institute's technology translation engine in diverse areas of research and technology development and to integrate the Institute's business development and technology commercialization efforts. She earned her Ph.D. in organic chemistry at the University of Geneva, Switzerland, and gained postdoctoral experience in the laboratory of Professor Gregory Verdine at Harvard University. Following her academic training, Angelika pursued her M.B.A. at Suffolk University, Boston, and subsequently held leadership positions at Ironwood Pharmaceuticals, and most recently at Catabasis Pharmaceuticals in Cambridge, MA, where she was Senior Vice President of Product Development. Her industry experience enabled her to gain a deep understanding of the processes involved in developing and de-risking therapeutic products from pre-clinical stages to the clinical market, including the regulatory approval process. She also serves on the Board of Directors of Bridgewell, a health and human services non-profit organization serving a wide range of constituents in day programs, residential housing and clinical services.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

Dr. John J. Talley is Co-Founder and Chief Scientific Officer of Euclises Pharmaceuticals, Inc. In addition, John is Co-Founder, Partner, and Vice President of Chemistry at Emmyon, Inc. John is an organic chemist who works to identify targets that can be modulated by chemicals. Currently, the two areas that John is focusing on are developing non-opioid treatments for acute and chronic pain and developing a new medicine that can be used with immune checkpoint inhibitors to slow or reverse tumor growth in cancer. In his free time, John enjoys cultivating vegetables and flowers in his garden, as well as growing indoor plants. Some of his other favorite activities include travel, camping with his family, and playing with his three cats. He received his BA in chemistry and science from Northern Iowa University and his PhD in organic chemistry from the University of Minnesota. Prior to joining the team at Euclises, John worked in various roles at Ironwood Pharmaceuticals, Pharmacia, Searle, Monsanto, and General Electric. John has received numerous honors and awards over the course of his career. He is co-inventor of seven marketed drugs, a named inventor on more than 215 U.S. drug patents, and a recipient of the prestigious PhRMA Foundation Discoverers Award. In our interview, John shares more about his life and research.

Mark Currie, President of R&D at Ironwood Pharmaceuticals, shares his amazing journey driving a product from establishing the foundation for the discovery of linaclotide by Ironwood scientists and leading every aspect of linaclotide's development and regulatory review. He shares his thought processes, pressure points, and lessons learned in leading the R&D team to get a product successfully to market. For more information on the Chief Medical Officer Summit and details for the 7th annual program taking place April 4-5, 2019 in Boston, please visit theconferenceforum.org

Today in FirstWord:

Founded as Microbia to explore and develop antifungal and antibacterial drugs, Ironwood Pharmaceuticals now has two drugs on the market helping patients with IBS and Gout. After nearly 20 years and many different approaches and targets, founder and CEO Peter Hecht tells Venrock’s Bryan Roberts that he is proud of the failures along the way as the end goal was always to build an enduring pharmaceutical company. The key is to kill programs that aren’t working early and not let them go too long – research is cheap, development is hard. Hecht also talks about managing people when you have a moving target. You have to have great people with the right skill sets and you have to help people who don’t have the right experience move on to a new challenge. Hecht’s superpower? Knowing what he doesn’t know. Though Roberts thinks it is Hecht’s ability to attract a variety of assets – people, ideas, capital...

Tom Graney, CFO, Ironwood Pharmaceuticals